Clinical trial
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
NCT00135304 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00135304 |
|---|---|
| Title | ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism |
| Official title | ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar® and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Secondary Hyperparathyroidism |
| Intervention type | Drug |
| Interventions | Sensipar®, Vitamin D |
| Enrollment | 170 |
| Start date | Aug 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Aug 26, 2005 |
| Last update posted | Feb 11, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: